Key result
This commentary argues that elevated endogenous xylitol is associated with cardiovascular risk rather than dietary intake, critiquing prior claims of its prothrombotic effects.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We therefore find the title of this publication misleading. It should say: 'Endogenous xylitol production is elevated in patients with cardiovascular risk' and 'Xylitol intake might have a short-term effect on thrombocyte aggregation'.”
“a blood concentration alone does not identify their source”
The authors argue against a causal link between dietary xylitol and cardiovascular risk, suggesting that elevated levels in CVD patients reflect metabolic dysregulation and endogenous production.
This commentary refers to ‘Xylitol is prothrombotic and associated with cardiovascular risk’, by M. Witkowski et al., https://doi.org/10.1093/eurheartj/ehae244 and the discussion piece ‘Erythritol and xylitol and CVD risk: a growing concern’, by M. Witkowski and S.L. Hazen, https://doi.org/10.1093/eurheartj/ehae729; ‘Elevated serum xylitol levels and cardiovascular risk: an active component or an innocent bystander?’, by M. Bonomini et al., https://doi.org/10.1093/eurheartj/ehae731. Recently, Witkowski et al.1 provided observational data linking fasting plasma xylitol levels to the risk of cardiovascular (CV) events and in vitro, in vivo animal, and ex vivo human studies suggesting that xylitol may promote platelet activation and thrombus formation. The limitation of observational clinical studies is that, by design, they can only show association, not causation. Although xylitol is known as a sweetener, the findings in cohorts with CVD reflect endogenous synthesis, which is unrelated to consumption, as noted by the authors.1 Moreover, when reporting metabolomic data, usually no single metabolites, but clusters of metabolites are shown. Emerging evidence shows that various diseases are associated with an upregulation of endogenous polyol production. Unfortunately, the authors offer no hypothesis why xylitol production is increased in their cohorts, which might deepen our understanding of metabolic dysregulation. The authors also report that ex vivo platelet response to stimulation with TRAP6 and ADP 30 min after ingestion of 30 g xylitol in 10 healthy humans was increased. However, with n = 10, the study was small; there was no placebo arm and only a single timepoint after ingestion. Short-term thrombocyte aggregation is e.g. altered in response to physical exertion and acute food intake. The single timepoint after 30 min does not allow drawing any conclusions about how relevant this observation is in the context of other natural fluctuations. We therefore find the title of this publication misleading. It should say: ‘Endogenous xylitol production is elevated in patients with cardiovascular risk’ and ‘Xylitol intake might have a short-term effect on thrombocyte aggregation’. Xylitol actually began its ‘career’ in Germany in the early 1970s, as a component of infusion products for critically ill patients. BFARM in Germany and Pmda in Japan approved a maximum i.v. dose of xylitol of 3 g/kg/day and 100 g/day, respectively, a stratospheric dose in comparison, which should have led to severe CV events. The only harmful but extremely rare side effect is the occurrence of severe secondary oxalosis after huge i.v. xylitol doses of >300 g/day, as recently reported in Japan in a patient who received a maximum dose of 500 g/day and a total dose of 2925 g in 8 days.2 In addition, alditols and monosaccharides (AME) from sorghum vinegar have been shown to inhibit several steps in the platelet aggregation pathway.3 Alditols and monosaccharides potently inhibited cyclooxygenase-1 (COX1) and thromboxane A2 synthase and attenuated thromboxane A2 production. Computational docking showed that alditols, such as erythritol and xylitol, could dock directly into the active site of COX. Bordier et al.4 have shown that 5 weeks of either erythritol or xylitol consumption had no significant effect on vascular function, abdominal fat, or glucose tolerance in obese people. One final note, in the accompanying editorial,5 the authors misquoted: ‘… Very recent studies in humans show that transaldolase deficiency may cause dramatic accumulation of blood sugar alcohols (in the case of erythritol, several hundred-fold!) and may cause liver cancer.10’ Instead, the reference in number 10 cites a paper on the anticancer effects of xylitol, a kind of Freudian slip. B.K.W. and A.C.M.-G.: nothing to declare. A.A.: founder and major shareholder of CoreQuest and Iperboreal Pharma.
No takes yet. Share an insight, caveat, or question.
Wölnerhanssen et al. (2024) reported a letter. Xylitol exposure was evaluated. This commentary argues that elevated endogenous xylitol is associated with cardiovascular risk rather than dietary intake, critiquing prior claims of its prothrombotic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: